Thymalin
Thymalin • Also called Thymalin Peptide
Thymalin is another immune- and longevity-oriented peptide that appears in peptide catalogs, but we do not currently have a clear FDA compounding category or approved-drug path for it.
Current status
Restricted
Immune and longevity interest, with current federal compounding constraints still in play.
FDA category
No clear FDA signal
Can pharmacies compound this?
No
Reclassification expected?
Unclear
This is a tracked search term, not a peptide with a defined FDA status signal we can point to today.
Primary Use
Immune and longevity interest
Also searched as
Thymalin Peptide
Regulatory Timeline
Mar 23, 2026
Current status signal recorded: No clear FDA category, warning-letter placement, or approved-drug pathway identified yet; current restriction is an inference from the lack of a documented lawful compounding basis..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Thymalin status changes
State-specific notes
California
Specialty longevity peptides remain difficult to source without clearer federal support.